Cohance Lifesciences , a leading integrated Contract Development and Manufacturing Organization (CDMO), has announced a significant leadership change in its CDMO division. The company has appointed Yann D'Herve as the new Chief Executive Officer of its CDMO business, effective August 1, 2025.

New Leadership for CDMO Division

Mr. D'Herve brings a wealth of experience to Cohance Lifesciences, with a strong track record in senior-level leadership across the pharmaceuticals, healthcare, and specialty chemicals sectors. His appointment comes as part of the company's strategy to accelerate the growth of its CDMO platform.

Extensive Industry Experience

Prior to joining Cohance, D'Herve held several key positions at Evonik, including:

• Senior Vice President and General Manager of Evonik's Healthcare division
• Vice President of Sales and Services
• Various divisional leadership assignments

In his most recent role at Evonik, D'Herve was responsible for 2,600 employees across nine manufacturing sites, with full P&L responsibility, including the company's CDMO business.

Educational Background

Mr. D'Herve's educational qualifications include:

• MBA from Université de Picardie Jules Verne in Amiens
• Master's degree in chemistry from CPE, Lyon, France

Leadership Transition

The appointment of Yann D'Herve coincides with the resignation of Dr. Sudhir Kumar Singh, who previously led the CDMO business as Chief Executive Officer. Dr. Singh will step down from his role effective July 31, 2025, but will remain available to facilitate a seamless transition.

Management Comments

Vivek Sharma, Executive Chairman of Cohance Lifesciences Ltd., expressed enthusiasm about the new appointment:

"We are delighted to welcome Yann to Cohance. His deep experience in leading multifaceted global pharmaceutical services businesses will be of tremendous benefit in accelerating the growth of our CDMO platform."

Yann D'Herve shared his excitement about joining Cohance:

"I am excited to join a growing CDMO with differentiated technologies such as ADCs and oligonucleotides and a strong global asset base. I look forward to working with the Cohance team to support the development and manufacturing of life-saving drugs for our partners."

This strategic appointment underscores Cohance Lifesciences' commitment to strengthening its position in the global CDMO market and enhancing its capabilities in small molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry.

Cohance Lifesciences Limited , formerly known as Suven Pharmaceuticals Limited, has received a compounding order from the Reserve Bank of India (RBI) related to past transactions involving ZCL Chemicals Limited (ZCL). The order, which typically addresses regulatory compliance matters, has been settled with the central bank.

Key Details of the Compounding Order

• The order, dated July 18, 2025, pertains to alleged violations of the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019.
• These violations were connected to certain foreign investments in ZCL Chemicals Limited in 2021, before its merger with Cohance Lifesciences.
• The company is required to pay a compounding fee of ₹8.30 crore (₹8,29,88,900) to the RBI within 15 days of the order.

Background and Corporate Structure Changes

• ZCL Chemicals Limited merged with erstwhile Cohance Lifesciences Limited, effective February 1, 2024.
• Subsequently, erstwhile Cohance Lifesciences merged with Suven Pharmaceuticals Limited, effective May 1, 2025.
• The merged entity was renamed Cohance Lifesciences Limited on May 7, 2025.

Financial Impact and Compliance

• The financial statements of erstwhile Cohance for the year ended March 31, 2025, had already made provisions for the compounding fee.
• Cohance Lifesciences stated that there is no additional impact on its financial, operational, or other activities beyond the compounding amount.
• The company received post-facto approval from the Department of Pharmaceuticals, Government of India, in 2022 for the transactions in question.

Regulatory Disclosure

The company has made this disclosure in compliance with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. The disclosure aims to keep shareholders and the market informed about significant regulatory developments affecting the company.

Cohance Lifesciences' proactive approach in addressing and settling this regulatory matter demonstrates its commitment to compliance and transparency in its operations. The resolution of this issue allows the company to move forward without the overhang of unresolved regulatory concerns.